Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab-Reference-Cited by-同舟云学术

Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab

Published:2019-10 Issue:10 Volume:45 Page:1360-1371
ISSN:0342-4642
Container-title:Intensive Care Medicine
language:en
Short-container-title:Intensive Care Med

Author:

Hotchkiss Richard S.,Colston Elizabeth,Yende Sachin,Crouser Elliott D.,Martin Greg S.,Albertson Timothy,Bartz Raquel R.,Brakenridge Scott C.,Delano Matthew J.,Park Pauline K.,Donnino Michael W.,Tidswell Mark,Mayr Florian B.,Angus Derek C.,Coopersmith Craig M.,Moldawer Lyle L.,Catlett Ian M.,Girgis Ihab G.,Ye June,Grasela Dennis M.

Funder

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Subject

Critical Care and Intensive Care Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00134-019-05704-z.pdf

Reference44 articles.

1. Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, Angus DC, Reinhart K (2016) Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 193:259–272

2. Liu V, Escobar GJ, Greene JD, Soule J, Whippy A, Angus DC, Iwashyna TJ (2014) Hospital deaths in patients with sepsis from 2 independent cohorts. JAMA 312:90–92

3. Rhee C, Dantes R, Epstein L, Murphy DJ, Seymour CW, Iwashyna TJ, Kadri SS, Angus DC, Danner RL, Fiore AE, Jernigan JA, Martin GS, Septimus E, Warren DK, Karcz A, Chan C, Menchaca JT, Wang R, Gruber S, Klompas M, Program CDCPE (2017) Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA 318:1241–1249